We were exploring ways of developing peptides that bind selectively, and we were very successful at that, but then we confronted the problem that our short, 23-residue peptides are not promising therapeutic candidates primarily because they cannot get into cells, Keating says
Kumari A, Singh RK, Kumari R, Monalisa SS (2023) Green synthesis and physical properties of crystalline silica engineering nanomaterial from rice husk (agriculture waste) at different annealing temperatures for its varied applications
Key genes were screened using machine learning methods such as Least Absolute Shrinkage and Selection Operator (LASSO), recursive feature elimination-random forest (RFE-RF), and support vector machine (SVM), and further validated using a multilayer perceptron (MLP) model
But pharma is taking back the wheel: Novo launched cash-pay Wegovy via NovoCare at $499/month then ended a partnership with Hims over continued off-label compounding (source) Lilly is offering Zepbound via LillyDirect while suing DTC platforms in CA (source) Hims is hedging with a ZAVA acquisition to expand GLP-1 sales in the EU (source) Most commentary stops at the what. I wanted to understand why
Theres at least one study underway to try to answer some of those questions
